Kornimate/medical-research-clean huggingface dataset:
high resolution ir imaging for diagnosis in the acute limping child - thermlimp

Conditions: Limping

Summary: a variety of different diseases may cause a limp in a child, and in younger children it is particularly challenging to isolate the area affected. children of this age group are unable to identify a specific region of pain, so clinical examination and parental interpretation is the only method of localising the area of discomfort. potential problems that may affect children include inflammation, fractures, infection, juvenile arthritis or movement in the growth plate in the hip, among other diseases. aside from an obvious source of injury, it is challenging for a clinician to distinguish between these different potential causes or the area of the problem without repeated visits, non-specific blood tests and the use of x-ray imaging: a form of radiation that carries with it a small risk of carcinogenic effect. once a region of the lower limb is identified, an x-ray image of the affected area is often taken; however, it is not possible to image the entire leg, so the importance of the initial examination by a clinician is evident. the aim of this research project is to assess the potential of high resolution infrared (ir) imaging technology in the identification of a focus for the cause of a limping child. the ir camera used for imaging is able to observe an entire limb, so the need to localise an area for imaging would be removed. in addition, if successful, infrared imaging could reduce the number of children exposed to x-ray radiation unnecessarily, whilst stream-lining medical practice by reducing the time to make a diagnosis along with unnecessary visits and tests. the investigators aim to explore whether non-invasive ir thermographic camera imaging assists with the clinical diagnosis in children presenting with an acute limp. this study represents a pilot evaluation as a test of concept.


Eligibility criteria:
inclusion criteria: * children age 9 months -16 years old who attend the emergency department (ed) of the sheffield children's hospital for an acute (less than 48 hours) limp. inclusion is subject to both the patient and carer having read (or being read to in very young children) the information sheets and both the patient and carer consenting to participate. exclusion criteria: * children with multiple injuries (e.g. those involved in serious car accidents), or those who have difficulty understanding the nature of the study (e.g. non-native english speakers, those with disabilities impairing their understanding of the study etc.) will be excluded. patients/carers in whom consent has not been obtained or refused will also be excluded. children who attend the ed with safeguarding concerns or in whom child protection suspicions arise during the consultation will be excluded. these children have a separate assessment process which would be significantly different to the study cohort.
a study of tongue conservation surgery for oral tongue cancer

Conditions: Tongue Cancer; Chemotherapy Effect; Surgery

Summary: this is an open-label, non-comparative phase ii clinical trial to assess efficacy and safety of tongue conservation treatment with sequential induction chemotherapy, tongue conservation surgery and postoperative concurrent chemoradiotherapy (ccrt) in patients with advanced oral tongue cancer.

surgical resection remains the most important component of standard treatment for oral tongue cancer, but may lead to profound functional impacts not effectively compensated by reconstruction surgery. the volume of tongue resection remains one key factor for the post-treatment deterioration of the functional outcomes and quality of life in large oral tongue cancer. primary chemoradiotherapy without surgical resection has not been accepted for oral tongue cancer because of the concerns about possible poorer response and sequelae. breast conservation treatment, by the sequential use of induction chemotherapy (ict), limited surgical resection and chemoradiotherapy, has become a standard treatment for human breast cancer of various stages. however, similar tongue conservation treatment for advanced oral tongue cancer has not been studied in trials. based on these data, it will be reasonable, in locally advanced (\> 3 cm) resectable oral tongue cancers, to test whether ict followed by tongue conservation surgery and postoperative ccrt can safely enhance the possibility of tongue conservation with improved post-treatment functions.

Eligibility criteria:
inclusion criteria: * patients with histological proof of squamous cell carcinoma of oral tongue * b. ct2-4, n0-2,m0, by clinical or radiographic examinations * either mandibulotomy, mandibulectomy or flap reconstruction is required by standard surgical planning * eastern cooperative oncology group (ecog) performance status of 0-1 * between 20 and 70 years of age * adequate hematopoietic function as defined below: hemoglobin \>= 10g/dl absolute neutrophil count (anc) \>= 1,500/µl platelets \>= 100,000/µl * adequate organ function as defined below: total bilirubin, alanine aminotransferase (alt), aspartate aminotransferase (ast), creatinine \ 50 ml/min * signed study-specific consent form prior to study entry exclusion criteria: * patients received gross oral tongue tumor resection before evaluation * primary subsites other than oral tongue * histologic diagnosis other than squamous cell carcinoma * patient with synchronous primary cancers (within 6 months) * clinical or radiographic findings as below: t1 tumors gross invasion to mandible, tonsil or \>1/3 base of tongue n3 disease or distant metastasis (m1) * prior head and neck chemotherapy or radiotherapy * prior esophageal cancer history * active cardiac disease defined as: unstable angina, uncontrolled arrhythmia, myocardial infarction within 6 months. * severe chronic obstructive pulmonary disease (copd) requiring ≥ 3 hospitalizations over the past year * mental status not fit for clinical trial. * pregnant or breast feeding women, or women of child-bearing potential unless using a reliable and appropriate contraceptive method.
the impact of red meat and whole-grains intake on the colonic mucosal barrier

Conditions: Mucus Colitis; Inflammation, Colon; Dietary Exposure

Summary: this study evaluates the impact of red meat and whole-grain intake on the colonic mucosal barrier and the dietary impact of these groups on the induced low-grade inflammation

the mucus layer in the colon is a continuous barrier separating the epithelial cells from faecal enzymes, bacteria, toxic and other components. the colonic mucus layer in patients with crohn's disease and ulcerative colitis was previously demonstrated to be thinner and more permeable compared to healthy subjects. the colonic mucus is composed of glycoproteins held together trough unstable disulfide bridges. the digestion of red meat is associated with monosulfide production, which could bind to the disulfide molecules, make more stable trisulfide molecules, and thus destroy the mucus architecture. moreover, different bacteria were previously linked to red meat intake and were associated with a degradation of the colonic mucus such as akkermansia muciniphila. from the other side, the fermentation of the undigested fibres, primarily in whole-grains, is associated with the production of short-chain fatty acids, which was related to a local anti-inflammatory effect. in this study, we hypothesise: 1. high consumption of red meat is associated with a thinner colonic mucus layer; 2. high consumption of whole-grain fibres is associated with a thicker colonic mucus layer; 3. mucin-2 gene expression is different between patients with high red meat consumption vs low red meat consumption; 4. mucin-2 gene expression is different between patients with high whole-grain consumption vs low whole-grain intake; 5. the level of inflammatory markers in blood "il-1beta, il-4, il-6, il-10, hs-crp, and tnf-alfa is higher in subjects with high red meat and low whole-grain intake.

Eligibility criteria:
inclusion criteria: * subjects referred to a colonoscopy in the hospital of southern denmark * subjects able to read and understand danish * mentally habile subjects * subjects who accept to be a part of the project exclusion criteria: * history of active cancer * a recent colonoscopy (less than 3 months ago ) * anamnesis of inflammatory bowel diseases.

Keywords: colonic mucus mucosal barrier red meat whole grain dietary fibers inflammation muc-2
understanding neonatal jaundice in rwanda

Conditions: Jaundice, Neonatal

Summary: this study exploits the distribution of low-cost high-quality phototherapy devices (brilliance by d-rev) to public hospitals in rwanda to assess whether the provision of improved technology improves health care for infant jaundice. specifically, the investigators are interested in measuring whether the provision of an additional high-quality phototherapy device, a known effective treatment for jaundice, successfully translates into improved care of neonatal jaundice in rwanda where the burden of jaundice is particularly high.

the ministry of health (mih) in rwanda has planned to provide brilliance devices (phototherapy) to 46 public hospitals in rwanda. the investigators have worked with mih to have the delivery of these machines be staggered over three phases through random selection. the methodology relies on the staggered distribution of brilliance devices and survey data collected prior and during delivery dates to evaluate the provision of low-cost high quality phototherapy machines, following the basic design of a staggered randomized controlled trial. specifically, the investigators will survey all hospitals prior to the receipt of any brilliance devices to provide a baseline description of the care received in these facilities. these surveys will collect information on the facility itself, including average infant jaundice caseloads and descriptions of recent cases. the investigators will then randomly select 15 hospitals to receive the brilliance units. three months after installation of brilliance has occurred at these facilities (group 1), another randomly selected subset of 16 facilities (group 2) will receive their brilliance machines. three months after these installations have been completed, the remaining facilities (group 3) will receive their brilliance machines. during this period, there will be ongoing data collection from the hospitals, creating a panel dataset on the jaundice-related caseloads at these facilities. the data collected will be akin to collecting hospital records of patients diagnosed with jaundice, but no identifiable patient information will be collected.

Eligibility criteria:
inclusion criteria: * for patient level record (de-identified), diagnosed by the facility for having infant jaundice * the facilities are included based on selection by the ministry of health for receiving additional phototherapy machines. exclusion criteria: -
an efficacy and safety comparison study of two marketed drugs in patients with relapsing-remitting ms

Conditions: Multiple Sclerosis, Relapsing-Remitting

Summary: the purpose of this study is to determine the difference in preventing a relapse between betaseron and avonex. patients with rrms currently treated with avonex will be randomized into 2 equal-size arms; one arm will continue on the standard dose of avonex; one arm will be converted to betaseron standard dose.

this study has previously been posted by berlex, inc. berlex, inc. has been renamed to bayer healthcare pharmaceuticals, inc.bayer healthcare pharmaceuticals, inc.is the sponsor of the trial.

Eligibility criteria:
inclusion criteria: * rrms patients that are receiving treatment with avonex 30 µg once weekly exclusion criteria: * primary progressive or secondary progressive ms
charlotte retention in care study

Conditions: HIV I Infection

Summary: the objective of the charlotte retention in care study is to assess if clinical decision support systems (cdss) that produce standardized alerts for measures of retention in care across clinics in the city of charlotte, north carolina have the ability to increase retention in care measures within clinics and in surveillance reports.

multiple charlotte hiv clinic providers are participating. "primary" hiv provider will be defined as the primary physician or advanced care practitioner following a patient, as recorded in their respective electronic health record (ehr) system and identified through chorus, a clinical decision support system (cdss) developed by epividian. the cdss will track patient case status as active or inactive (loss to follow-up, transferred medical care, or deceased). providers will be informed of the study and sites will be contracted to participate in this collaborative research study. this study was approved by the advarra institutional review board.

Eligibility criteria:
inclusion criteria: * hiv-1+ * any gender * 18 years old or older * residing in the charlotte, north carolina metropolitan area * at least a single entry in the ehr in the last 2 years
detection of enterovirus genotypes by crispr technology

Conditions: Enterovirus Infections

Summary: crispr-enterovirus detection system was constructed in this study for detection variety genotypes of enterovirus rapidly in children suspected or diagnosed as enterovirus infection.

to construct crispr-enterovirus detection system, we screened the targets, primers and crrna and evaluated the capability of this detecting system. samples of feces, blood and cerebrospinal fluid (the remainder of routine testing samples) from 500 children with suspected or confirmed enterovirus infection were examined using the crispr technique. to evaluate the crispr-enterovirus detection system, real-time pcr and traditional pcr as comparison method was implemented. the method of real-time pcr and traditional pcr were used to detect enterovirus and analyze the genotypes of enterovirus, respectively. according to the results of crispr-enterovirus detection system and the comparison method, the positive coincidence rate, negative coincidence rate and consistency of the two methods were calculated. furthermore, the sensitivity and specificity of the crispr-enterovirus detection system for detection of enterovirus were calculated.

Eligibility criteria:
inclusion criteria: * patients with clinically suspected or confirmed enterovirus infection exclusion criteria: * patients with clinical diagnosis of non-enterovirus infection
efficacy and safety of leningrado 5 association in the treatment of hypertension

Conditions: Arterial Hypertension

Summary: the purpose of this study is to evaluate the efficacy and safety of leningrado 5 association on the treatment of hypertension.


Eligibility criteria:
inclusion criteria: * participants aged 18 years or more; * participants diagnosed with hypertension, not controlled by monotherapy and/ or lifestyle modification; exclusion criteria: * any clinical and laboratory findings that, in the judgment of the investigator, may interfere with the safety of research participants; * bp ≥ 180/110 mmhg; * participants with bmi (body mass index) ≥ 40 kg/m2; * previous diagnosis of secondary hypertension; * history of target organ injury; * history of cardiovascular, hepatic and renal disease; * history of gout, diabetes mellitus and hypokalemia; * current medical history of cancer; * current smoking; * history of alcohol abuse or drug use; * pregnancy or risk of pregnancy and lactating patients; * known allergy or hypersensitivity to the medicines components used during the clinical trial; * participation in clinical trial in the year prior to this study.
whole body pet-mri in paediatric and adolescent lymphoma

Conditions: Lymphoma

Summary: children and adolescents with hodgkin lymphoma currently undergo multiple investigations including a separate pet and mri scans during their treatment. investigators want to investigate if a combined pet-mri scan could give the same information. children who join our study will have an extra scan twice during their treatment

children and adolescents with hodgkin lymphoma currently undergo multiple investigations including a separate pet and mri scans during their treatment. investigators want to investigate if a combined pet-mri scan could give the same information. children who join our study will have an extra scan twice during their treatment routine whole body clinical mri will be performed according to current clinical standard of care. axial and coronal imaging from the maxilla to proximal femurs will be performed using a combination of t1 and t2 weighted sequences, with and without gadolinium administration.

Eligibility criteria:
inclusion criteria: 1. suspected or histologically confirmed hodgkin lymphoma 2. male or female participants 3. age 0-20 years inclusive 4. entered into the euronet phl-c1 trial, lp1 trial or successor euronet trials, including euronet phl c2 due to open from 2013 onwards or planned to receive chemotherapy regimens of said trials without being formally entered into the trial. 5. participant/guardian/parental written informed consent exclusion criteria: 1. participants with contraindications to mri (including cardiac pacemakers or non-mri compatible intracranial vascular clips) 2. participants who are pregnant or nursing
choroidal thickness in myopes by ssoct

Conditions: ESRD

Summary: optical coherence tomography is a non-invasive and non-contact imaging modality that enables two-dimensional cross-sectional and three-dimensional volumetric imaging of tissue architecture.

it has evolved over the past decade as one of the most important ancillary tests in ophthalmic practice. it is a noninvasive imaging technique and provides high resolution, cross-sectional images of the retina, the retinal nerve fiber layer and the optic nerve head. with axial resolution in the 5-7 μm range, it provides close to an in-vivo 'optical biopsy' of the retina. optical coherence tomography employs light from a broadband light source, which is divided into a reference and a sample beam, to obtain a reflectivity versus depth profile of the retina. the light waves that are back scattered from the retina, interfere with the reference beam, and this interference pattern is used to measure the light echoes versus the depth profile of the tissue in vivo. recently, a new type of optical coherence tomography instrument, called a swept source optical coherence tomography, was introduced. the swept source optical coherence tomography uses a tunable laser (swept-source) as a light source with a longer wavelength that allows the light to penetrate deeper into tissues than the conventional spectral domain optical coherence tomography instruments. this, then, enabled the imaging of the choroid. because choroidal abnormalities such as vascular hyperpermeability, vascular changes, loss and thinning are critical to the onset and progression of many ocular diseases, ophthalmologists and researchers are shifting their interest to the choroidal abnormalities. being a major vascular layer of the eye , choroid plays an important role in ocular health, and is involved in the pathogenesis of many intraocular diseases such as age-related macular degeneration , polypoidal choroidal vasculopathy , central serous chorioretinopathy and myopic macular degeneration. accurate measurement of choroidal thickness in vivo is an essential step in monitoring disease onset and progression that lead to choroidal thinning. based on histologic study, choroidal thickness ranges from 170 to 220 um. these disorders show the need for understanding the choroidal structure in ocular diseases and the importance of having database of choroidal thickness.

Eligibility criteria:
inclusion criteria: * age from 18 years to 40 age. * spherical equivalent from zero to -8. * minimum corneal thickness from 500 to 540. * refractive power of cornea more than 41 diopter. * axial length from 22 to 26. exclusion criteria: * corneal abnormalities such as ectasia. * eyes with dystrophic or degenerative diseases. * prior ocular surgery. * anterior or posterior segment inflammation. * glaucoma. * eyes with choroidal abnormalities or conditions that could affect choroidal thickness such as central serous chorioretinopathy, nevus, pregnancy, or haemangiomas. * patients with diabetes mellitus. * patients with optical media opacity that significantly disturb optical coherence tomography image acquisition.
impact of calory restriction and biofeedback on endocrine and mental health

Conditions: Neuroendocrinology; Mental Stress; Psychological; Obesity

Summary: backgroup/relevance: overweight and obesity, defined by a respective body mass index of above 25 and 30 kg/m2, are getting increasingly common in all regions of the world. obesity is currently estimated to be present in more than 10% of the global population while overweight roughly reached an estimate of 40% in 2016. overweight dramatically increases the risk for a wide range of disorders such as diabetes mellitus and other metabolic and cardiovascular disorders subsumed under the term metabolic syndrome, increasing the risk for life-threatening cardiovascular events such as myocardial infarction and stroke. similar to other chronic diseases such as mental health disorders, prescribing medication was oftentimes insufficient and should be complemented by patient empowerment to reach sufficient treatment adherence and control of lifestyle factors. thereby, overweight and obesity can easily be challenged by patients themselves without pharmacological intervention. overweight may place central in the crossroad between metabolic and mental health for several reasons. excessive body fat is known to cause subclinical inflammation that was also associated with many psychiatric disorders such as major depression. similarly, the hypothalamic-pituitary-adrenal axis relevant for stress response was shown to be dysregulated in both metabolic and mental health disorders. study design: in this study, non-pharmacological interventions are applied in healthy women with overweight or obesity and self-perceived psychological stress. women staying at the "la pura" women´s health resort (www.lapura.at/) are invited to partake in the study and receive a short-term intervention of calory restriction. thereby, either f.x. mayr or very-low-calory-diet (vlcd) will be applied, reducing calory intake to 700-800 kcal/die. following random assigment to four treatment arms, half of the women also receive a 7-session clinical-psychological intervention consisting of biofeedback, individualized psycho-education on stress prevention and mindlessness training. women are assessed at baseline and after two weeks of interventions for metabolic parameters such as insulin functioning, anthropometric parameters such as body weight and body fat, blood parameters such as sex hormones, fat metabolism and liver function, parameters of neuroplasticity such as brain derived neurotrophic factor (bdnf), as well as psychological and biological stress correlates and mental health symptom dimensions.


Eligibility criteria:
inclusion criteria: * women willing to undergo two-weeks of calory restriction * at least 18 years of age exclusion criteria: * currently pregnant * any acute or a severe chronic illness